Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.

Abstract

BACKGROUND Interferon beta (IFNbeta) effectively reduces disease activity in patients with multiple sclerosis (MS). Neutralizing antibodies (NAbs) can diminish or abolish the clinical efficacy of IFNbeta therapies. Biomarkers of the IFNbeta response, such as myxovirus resistance protein A (MxA), viperin, and interferon-induced protein with tetratricopeptide… (More)
DOI: 10.1212/WNL.0b013e3181bf98db

Topics

5 Figures and Tables